Buy Ipamorelin – Peptide Partners

Product Overview & Specifications

Ipamorelin is a selective growth hormone-releasing peptide (GHRP) analog investigated for its activity at the ghrelin/growth hormone secretagogue receptor. Peptide Partners supplies this research-grade material for in-vitro testing, laboratory experimentation, receptor pharmacology, structural biology, and preclinical metabolic research.

Published studies have examined ipamorelin using primary pituitary cell cultures, receptor binding assays, in vivo animal models, LC-HRMS detection methods, and reproductive axis investigations. Research areas include GH secretagogue receptor selectivity, pituitary hormone release mechanisms, reproductive hormone interactions, analytical detection methodologies, and peptidomimetic compound characterization.

The product name supplied for this listing is “Ipamorelin.” Researchers should verify the exact identity, sequence, formulation, and batch-specific certificate of analysis before beginning any experiment. Findings from published ipamorelin studies should not be assumed to apply to every commercial batch or formulation.

Product Specifications

Specification	Details
Product name	Ipamorelin
Compound type	Selective growth hormone-releasing peptide (GHRP) analog
Primary molecular targets	Growth hormone secretagogue receptor (ghrelin receptor)
Primary research areas	GH secretagogue receptor pharmacology, pituitary cell signaling, reproductive axis modulation, analytical detection methods, and peptidomimetic characterization
Product format	10 mg vials
Vial size	10 mg
Vial capacity	3 mL
Available box combinations	20 mg, 50 mg, 100 mg, and 200 mg
Multi-vial purity	99.92%
Independent testing	Yes
Endotoxin screening	Passed
Heavy-metals screening	Passed
Purity screening	Passed
Manufacturer ID	WF03
Batch ID	IP202601
Cost per milligram	$2.88–$4.10

The stated 99.92% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

Ipamorelin, the First Selective Growth Hormone Secretagogue

Authors: K Raun, B S Hansen, N L Johansen, H Thøgersen, K Madsen, M Ankersen, and P H Andersen

Publication: European Journal of Endocrinology, 1998

PMID: 9849822

Reference: View publication

This study characterized ipamorelin as a selective growth hormone-releasing peptide using in vitro and in vivo experimental approaches. In vitro experiments using primary rat pituitary cells demonstrated that ipamorelin released growth hormone (GH) with potency and efficacy similar to GHRP-6 (EC50 = 1.3±0.4 nmol/L and Emax = 85±5% vs 2.2±0.3 nmol/L and 100%).

Pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists demonstrated that ipamorelin stimulates GH release via a GHRP-like receptor. Specificity studies in swine showed that ipamorelin did not affect FSH, LH, PRL, or TSH plasma levels.

Unlike GHRP-6 and GHRP-2, which increased plasma ACTH and cortisol levels, ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation. This selectivity was evident even at doses more than 200-fold higher than the ED50 for GH release. The researchers concluded that ipamorelin is the first GHRP-receptor agonist with GH release selectivity similar to that displayed by GHRH.

Plain-English Research Summary

This study shows that ipamorelin effectively stimulates growth hormone release in laboratory experiments while being highly selective. Unlike similar compounds, it does not trigger the release of stress-related hormones like cortisol or ACTH, even at very high doses. This selectivity makes ipamorelin a valuable research tool for studying GH secretagogue receptor pharmacology without confounding stress-hormone effects.

The Influence of Ghrelin Agonist Ipamorelin Acetate on the Hypothalamic-Pituitary-Testicular Axis in a Cichlid Fish, Oreochromis mossambicus

Authors: Mallikarjun Gouda and C.B. Ganesh

Publication: Animal Reproduction Science (ScienceDirect), 2024

DOI: 10.1016/j.anireprosci.2024.107141

Reference: View publication

This study investigated the effects of ipamorelin acetate (IPA) administration on the reproductive axis in tilapia fish (Oreochromis mossambicus). Fish were administered either 5 or 30 µg of IPA for 21 days, resulting in a significant and dose-dependent increase in food intake compared to the control group.

Treatment led to significant increases in the numbers of primary spermatocytes, secondary spermatocytes, and early spermatids. Fish treated with 30 µg of IPA showed significant increases in late spermatids, as well as the areas of the lobule and lumen, compared to controls. There was no significant difference in GnRH-immunoreactive fibers in the hypothalamus and anterior pituitary gland across groups.

However, a significant elevation in androgen receptor protein expression was observed in fish treated with 30 µg of IPA. Serum concentrations of luteinizing hormone (LH) and 11-ketotestosterone (11-KT) were significantly elevated in both treatment groups compared to controls. The researchers concluded that ghrelin agonist administration enhances germ cell development during meiosis-I, potentially mediated via stimulation of 11-KT and androgen receptors at the testicular level and LH at the pituitary level.

Plain-English Research Summary

This research examined how ipamorelin affects reproductive development in fish. The compound increased food intake and promoted sperm cell development, with higher doses producing more mature sperm cells and larger reproductive tissues. The treatment elevated reproductive hormones (LH and 11-KT) and androgen receptor expression, suggesting ipamorelin influences the reproductive axis through complex hormonal interactions in this animal model.

Detection of the Synthetic Peptide Ipamorelin in Dried Blood Spots by Means of UHPLC-HRMS

Authors: Enrico Gerace, Jessica Modaffari, Pierre Negri, Daniele Di Corcia, Eleonora Amante, Alberto Salomone, and Marco Vincenti

Publication: Journal of the American Society for Mass Spectrometry (ScienceDirect), 2021

DOI: 10.1007/s13361-021-00011-7

Reference: View publication

This study developed and validated an analytical method for detecting ipamorelin in dried blood spots (DBS) using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). The procedure employed fast methanolic extraction followed by LC-HRMS detection.

MS and MS/MS data were collected using a Q-TOF mass spectrometer operating in positive electrospray ionization (ESI) mode. The method provided a simple, rapid, and effective approach for ipamorelin identification and quantification in DBS matrices.

The validated method demonstrated appropriate sensitivity, specificity, and reproducibility for detecting synthetic peptide compounds in biological samples. This analytical approach supports pharmacokinetic research, compound detection studies, and quality control applications in laboratory settings.

Plain-English Research Summary

Researchers created a new laboratory method to detect ipamorelin in dried blood samples. The technique uses advanced mass spectrometry to identify and measure the peptide quickly and accurately. This method is useful for research applications including analytical validation, compound tracking studies, and detection methodology development.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, weight-management product, performance-enhancing compound, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.